23 results on '"Cho, Eun Kyung"'
Search Results
2. A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors
3. Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies
4. A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation–Positive NSCLC Patients
5. Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset
6. Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial
7. Prognostic Significance of CT-Determined Sarcopenia in Patients with Small-Cell Lung Cancer
8. Pseudopathologic vertebral body enhancement in the presence of superior vena cava obstruction on computed tomography
9. A Cyclophilin from Griffithsia japonica Has Thermoprotective Activity and Is Affected by CsA
10. Comparison of Characteristics of Bacterial Bloodstream Infection between Adult Patients with Allogeneic and Autologous Hematopoietic Stem Cell Transplantation
11. P3.02b-053 A Randomized, Open Label, Phase II Study Comparing Pemetrexed plus Cisplatin versus Pemetrexed Alone in EGFR Mutant NSCLC after EGFR-TKI: QOL Data: Topic: EGFR Clinical
12. P2.03a-037 Prognosis of Advanced Non-Small Cell Lung Cancer (NSCLC) Refractory to First-Line Platinum Chemotherapy: Topic: Clinical Trials
13. P2.03a-038 Phase III Trial of Pemetrexed/Carboplatin vs Pemetrexed Only in Chemo-Naïve Elderly Non-SQCC NSCLC Patients Aged ≥ 70: Topic: Clinical Trials
14. MA07.07 Ceritinib in ROS1-Rearranged Non-Small-Cell Lung Cancer: An Update of Korean Nationwide Phase II Study
15. Induction Therapy with “3+7” Chemotherapy Plus ATRA Followed by Consolidations with Three Courses of Idarubicin Alone and Maintenance Therapy with ATRA in Newly Diagnosed Acute Promyelocytic Leukemia (APL) Has An Excellent Leukemia-Free Survival but Minimal Toxicity in Low and Intermediate Risk Groups.
16. A Phase II Study of Erlotinib as a First-Line Therapy for Patients with Non—Small-Cell Lung Cancer with Favorable Clinical Predictors
17. P1-226: Irinotecan plus carboplatin for patients with extensive-disease small cell lung cancer
18. P1-207: Concurrent chemoradiotherapy with irinotecan/cisplatin followed by consolidation chemotherapy with irinotecan/cisplatin in patients with limited-disease small cell lung cancer
19. P3-129: Second–line therapy with irinotecan or gefitinib in pretreated patients with non–small cell lung cancer: final results of a new treatment strategy according to clinical predictors for response
20. P3-128: Correlation of the epidermal growth factor receptor mutations with clinical outcomes in patients with non–small cell lung cancer treated gefitinib: an exploratory molecular analysis of a prospective phase II study
21. P2-297: Phase II trial of weekly docetaxel and gemcitabine for chemotherapy-naive patients with advanced non-small cell lung cancer
22. Evolution of FLT3 Internal Tandem Duplication at the Diagnosis, Relapse, Remission or Induction Failure during the Treatment in Acute Myeloblastic Leukemia.
23. Heparin-Induced Thrombocytopenia in Patients with Coronary Artery Disease: A Common but Underdiagnosed Syndrome.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.